Equities analysts expect that Charles River Laboratories International, Inc. (NYSE:CRL) will post sales of $796.73 million for the current quarter, Zacks reports. Seven analysts have provided estimates for Charles River Laboratories International’s earnings, with estimates ranging from $790.30 million to $808.71 million. Charles River Laboratories International posted sales of $707.06 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 12.7%. The business is expected to issue its next earnings results on Thursday, May 6th.
On average, analysts expect that Charles River Laboratories International will report full year sales of $3.39 billion for the current financial year, with estimates ranging from $3.31 billion to $3.44 billion. For the next financial year, analysts forecast that the company will report sales of $3.75 billion, with estimates ranging from $3.60 billion to $3.90 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Charles River Laboratories International.
Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Tuesday, February 16th. The medical research company reported $2.39 EPS for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.28. Charles River Laboratories International had a net margin of 10.68% and a return on equity of 22.41%.
In other news, CEO James C. Foster sold 30,000 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 11th. The stock was sold at an average price of $285.02, for a total value of $8,550,600.00. Following the sale, the chief executive officer now directly owns 255,041 shares in the company, valued at approximately $72,691,785.82. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Michael Gunnar Knell sold 410 shares of the firm’s stock in a transaction on Friday, February 19th. The stock was sold at an average price of $290.99, for a total value of $119,305.90. Following the completion of the sale, the chief accounting officer now directly owns 4,198 shares of the company’s stock, valued at approximately $1,221,576.02. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,741 shares of company stock worth $11,677,915. 1.90% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the company. Altshuler Shaham Ltd purchased a new position in shares of Charles River Laboratories International during the third quarter valued at about $28,000. Jeppson Wealth Management LLC purchased a new stake in Charles River Laboratories International in the third quarter worth about $29,000. Trust Co. of Vermont bought a new stake in Charles River Laboratories International during the 3rd quarter valued at approximately $31,000. Berman Capital Advisors LLC grew its holdings in shares of Charles River Laboratories International by 42.6% during the 4th quarter. Berman Capital Advisors LLC now owns 144 shares of the medical research company’s stock worth $34,000 after acquiring an additional 43 shares during the period. Finally, Archer Investment Corp bought a new position in shares of Charles River Laboratories International in the 4th quarter worth approximately $38,000. 92.30% of the stock is owned by hedge funds and other institutional investors.
CRL traded down $0.84 during trading on Thursday, reaching $282.75. The stock had a trading volume of 10,504 shares, compared to its average volume of 342,970. The business has a 50-day moving average of $274.86 and a 200-day moving average of $241.52. Charles River Laboratories International has a one year low of $95.58 and a one year high of $303.79. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.22 and a current ratio of 1.45. The stock has a market cap of $14.07 billion, a PE ratio of 47.27, a PEG ratio of 2.19 and a beta of 1.12.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
Featured Story: Percentage Decliners
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.